



[LMKaplan0@gmail.com](mailto:LMKaplan0@gmail.com)


## Long-term Outcomes of Metabolic Surgery

**Lee M. Kaplan, MD, PhD**

Professor of Medicine and Chief, Section of Obesity Medicine  
Director, Dartmouth Weight and Wellness Center  
Geisel School of Medicine at Dartmouth

[LMKaplan0@gmail.com](mailto:LMKaplan0@gmail.com)

3 September 2024



*Fernando Botero, 1932-2023*

**IFSO 2024 Pre-Course • Melbourne, Victoria, Australia**

# Disclosures


---

I am currently or have recently been a paid consultant to the following companies and organizations:

|                      |                     |
|----------------------|---------------------|
| Altimune             | Kallyope            |
| Amgen                | Eli Lilly & Company |
| AstraZeneca          | Neurogastrx         |
| Bain Capital         | Novo Nordisk        |
| Boehringer Ingelheim | Optum Health        |
| Cytoki               | Perspectum          |
| Ethicon              | Pfizer              |
| Gelesis              | Sidekick Health     |
| Gilead Sciences      | Skye Bioscience     |
| Glyscend             | twenty30.health     |
| Intellihealth        | Xeno Biosciences    |
| Johnson & Johnson    | Zealand             |

# Long-term weight loss after bariatric surgery

## Swedish Obesity Subjects Study



N=2010 surgical patients;  
2037 matched controls

### Operations

|                            |            |
|----------------------------|------------|
| Gastric bypass             | 13%        |
| <b>Banded gastroplasty</b> | <b>69%</b> |
| Gastric banding            | 18%        |

### Weight Loss


|                  |     |
|------------------|-----|
| 1 year post-op   | 25% |
| 20 years post-op | 18% |

**Average 28% weight regain**

# Long-term weight loss after bariatric surgery

## Randomized, controlled trial – medical vs. surgical therapy

Subjects with type 2 diabetes




# Surgery improves many metabolic and inflammatory complications of obesity

---

- Type 2 diabetes
- Hypertension
- Hyperlipidemia
- Fatty liver disease
- Chronic kidney disease
- Sleep apnea
- Heart failure with preserved ejection fraction (HFpEF)
- Refractory GERD (primarily gastric bypass)
- Osteoarthritis
- Autoimmune arthritis
- Cognitive dysfunction
- Cancer (at least 18 types)


# Bariatric surgery reduces mortality

## US Veterans Administration Experience







# Two major challenges for metabolic/bariatric surgery

---




# Weight loss varies widely among patients






# Variable response to surgery is driven by **biology**



Adapted from Bessler M *et al.*, *Surg Obes Rel Dis* 2008


Copyright © 2024 The Obesity and Metabolism Institute. All rights reserved

# Genetic factors are primary influence over RYGB-induced weight loss



\*p<0.05 vs. randomly paired or cohabitating; †separate study

# Variable response to surgery is driven by **biology**



Adapted from Bessler M *et al.*, *Surg Obes Rel Dis* 2008

Copyright © 2024 The Obesity and Metabolism Institute. All rights reserved


# Biological approaches to suboptimal initial weight loss

---


- Optimize a healthy lifestyle (**without** recommending purposeful calorie reduction)
- **Discontinue or substitute for** weight gain-promoting medications
- **Add a therapy** with a **complementary (additional) mechanism**
  - **Anti-obesity medication**
  - **Surgical conversion** to a procedure with **additional mechanism(s)**
  - **Endoscopic procedure** with a complementary mechanism

# Two major challenges for metabolic/bariatric surgery


---



# In obesity, the target fat mass is dysregulated (elevated) from environmental influences on biologically susceptible individuals




# Effective obesity treatments normalize fat mass regulation leading to decreased weight without activating metabolic adaptation



# Weight regain with different anti-obesity therapies


## Calorie reduction-based lifestyle therapy

Average maximum weight loss **7-8%**



## Metabolic/bariatric surgery

Average maximum weight loss **28-35%**







# Physiological weight loss is associated with blunting of metabolic adaptation

- Vehicle (placebo)
- Semaglutide, 9.7 nmol/kg/day
- ▲— Calorie restricted, weight-matched to semaglutide group

### Body weight



### Energy expenditure



# RYGB effects are opposite to those of restrictive dieting

|                         | Calorie restriction<br>(non-physiological) | Metabolic surgery<br>(physiological) |
|-------------------------|--|--------------------------------------|
| Energy expenditure      | ↓  | ↑                                    |
| Appetite                | ↑  | ↓                                    |
| Hunger                  | ↑  | ↓                                    |
| Satiety                 | ↓  | ↑                                    |
| Reward-based eating     | ↑  | ↓                                    |
| Stress response         | ↑  | ↓                                    |
| Gut peptides            |  |                                      |
| Ghrelin                 | ↑  | ↓                                    |
| GLP-1, PYY, CCK, amylin | ↓  | ↑                                    |

# Potential causes of recurrent weight gain

---

- **Promotion of non-physiological weight loss**
  - Restrictive dieting

# Bariatric surgery: defense of a decreased body fat mass

## Step 1:


- **Obese**, sham-operated controls (350 gm)
- **Thin**, chow-fed, unoperated (225 gm)
- ▲ **Thin, underfed** to match VSG weight (275 gm)
- ▼ **Thin**, underwent **VSG** (275 gm)

## Step 2:

Calorie restrict to lose 30% body weight

## Step 3:


Let them eat what they want



# Effect of **calorie restriction** beyond **physiological** weight loss


## STEP 1 Trial

Subjects without Diabetes  
Drug Alone



## STEP 3 Trial

Subjects without Diabetes  
Drug Plus Calorie Reduction




# Potential causes of recurrent weight gain

---

- Promotion of non-physiological weight loss
  - Restrictive dieting
- **Progression of disease**

# Most recurrent weight gain is NOT from surgical or patient failure

## Long-term Progression of Obesity




# Potential causes of recurrent weight gain

---

- Promotion of non-physiological weight loss
  - Restrictive dieting
- Progression of disease
- **Environmental factors**
  - Continued exposure to obesogenic environment
  - Environmental toxins
  - Chronic stress (e.g., emotional, sleep deprivation, PTSD)
  - Obesogenic diet
  - Obesogenic medications



# Environmental influences raise the defended fat mass



# Potential causes of recurrent weight gain


---

- Promotion of non-physiological weight loss
  - Restrictive dieting
- Progression of disease
- Environmental factors
  - Continued exposure to obesogenic environment
  - Environmental toxins
  - Chronic stress (e.g., emotional, sleep deprivation, PTSD)
  - Obesogenic diet
  - Obesogenic medications
- **Biological factors**
  - Genetic predisposition?  
Not as clear as for suboptimal initial weight loss

# Medical therapy for suboptimal weight loss or recurrent weight regain


If surgery worked mechanically (restriction or malabsorption) ...

... combination with medications would be **additive at most**



Since surgery works physiologically ...



... complementary mechanisms allow for **synergy**



# Postoperative pharmacotherapy augments surgical weight loss

## GRAVITAS Study

Liraglutide 1.8 mg vs. Placebo after Gastric Bypass  
Patients with Type 2 Diabetes



- Placebo
- Liraglutide


# Liraglutide 3.0 mg augments weight loss after metabolic surgery

## BARI-OPTIMISE Trial

Subjects with suboptimal (<20%) initial weight loss after metabolic surgery

Liraglutide 3.0 mg/day vs. placebo

(N=70)



# Potential means of addressing recurrent weight gain

---

## Cause of weight gain

Promotion of non-physiological weight loss  
(purposeful calorie restriction beyond what surgery naturally provides)

Progression of disease

Environmental factors

Surgical complication

Intrinsic biological or genetic factors

## Potential solution

**Avoid recommending purposeful calorie reduction – let the surgery do its job!**

Add an **additional therapeutic mechanism**

- Start or add an **anti-obesity medication**
- **Convert to a different MBS** operation
- Add a **complementary endoscopic** treatment

**Address the environmental factors** or  
add an **additional therapeutic mechanism**

Correct the **surgical anatomy**

Add an **additional therapeutic mechanism**

# Strategies for using medical-surgical combinations - 1

---

## Pre- and peri-operative medical therapy

- **Stepped care** (medical **followed by** surgical care)
  - Particularly appropriate for **lifestyle-based** medical treatment
  - Previous anti-obesity medications generally **stopped** at the time of surgery
- **Preoperative weight loss** – primary benefit is liver fat mobilization
  - Short-term calorie reduction or meal replacement
  - Anti-obesity medications
- **Simultaneous initiation of combination therapy**
  - Creates problem of **not knowing which drug will work best** in a particular patient
  - Because of synergy between surgery and medications, **preoperative medication response may not predict postoperative medication response**

# Strategies for using medical-surgical combinations - 2

---

## Postoperative medical therapy

- **Enhancement** of suboptimal post-operative weight loss
- **Rescue** of recurrent post-operative weight regain
- **Allows personalized approach** to account for patient-to-patient variability in response to medications
- **Amenable to standard sequential “trial-and-error” approach** to using anti-obesity medications



# Practical use of combination medical-surgical therapy

---

- Pharmacological treatment **after completion of surgical weight loss** is the most promising strategy
- Pharmacological treatment **works best for suboptimal initial weight loss**
  - There is also **benefit for recurrent weight gain**, but this use is less well studied
- Pursue a **step-wise treatment strategy** after surgery as you would before surgery
- Add new therapies after stable response to previous therapies (i.e., after reaching plateau)
- There are currently **no good predictors** for choosing the “right” medication for an individual patient
- **Drugs can be effective in combination with surgery that are ineffective alone**
- **Anticipate life-long use** of **successful** approaches



[LMKaplan0@gmail.com](mailto:LMKaplan0@gmail.com)


## Long-term Outcomes of Metabolic Surgery

**Lee M. Kaplan, MD, PhD**

Professor of Medicine and Chief, Section of Obesity Medicine  
Director, Dartmouth Weight and Wellness Center  
Geisel School of Medicine at Dartmouth

[LMKaplan0@gmail.com](mailto:LMKaplan0@gmail.com)

3 September 2024



*Fernando Botero, 1932-2023*

**IFSO 2024 Pre-Course • Melbourne, Victoria, Australia**